Absci and Other AI-Powered Biotechs Lead the Way in Antibody Discovery
AI-driven drug discovery is traditionally associated with small molecules. Things are changing rapidly.
The monoclonal antibody (mAb) market has seen impressive growth in recent years, with the top-selling drugs increasingly being mAbs. The success of these therapeutics has driven the pharma industry to seek innovative methods for refining and improving their antibody pipelines. Artificial intelligence (AI) and deep learning, which have…
Keep reading with a 7-day free trial
Subscribe to Where Tech Meets Bio to keep reading this post and get 7 days of free access to the full post archives.